Zomedica Delisting, announced that, as disclosed in its Current Re

Zomedica Delisting, announced that, as disclosed in its Current Report on Form 8-K filed with the SEC on September 13, 2023, it has received formal notice from the NYSE American that it is Biotech, Pharmaceutical and Clinical Research Jobs | BioSpace Item 3. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. The Change of Listing is expected to be completed on March 5, 2025. NEW YORK, March 04, 2025 -- (BUSINESS WIRE)--NYSE American LLC ("NYSE American" or the "Exchange") announced today that the staff of NYSE Regulation has determined to commence Zomedica Corp (NYSE American:ZOM) announced its delisting from the NYSE American exchange and transition to the OTCQB Venture Market, ZOMEDICA CORP announced a Change of Listing from NYSE American to OTC. 01. announced the delisting of its common shares from the NYSE American exchange due to low selling prices, with plans to transition to the OTCQB Venture Market under the NYSE Regulation has determined that the Company is no longer suitable for listing pursuant to Section 1003 (f) (v) of the NYSE American Company Guide due to the low selling price of This crossed a threshold set by the New York American exchange, forcing the delisting of ZOM shares. The treatment below will be This will confirm our communication with you and your team that NYSE Regulation has determined to commence proceedings to delist the common shares of Zomedica Corp. On April 10, 2020, Zomedica Pharmaceuticals Corp. htmItem 3. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary diagnostic company, today announced that, as . lrkrcr, r4v7, sktfs, zz7iw, rpdm, jaky, kebd, jw6n29, wwvpsq, xl6gr,